Alterations in intestinal microbiota of colorectal cancer patients receiving radical surgery combined with adjuvant CapeOx therapy
An intricate relationship exists and interactions occur between gut microbiota and colorectal cancer (CRC). Radical surgery combined with adjuvant chemotherapy (AC) serves as the mainstream therapeutic scheme for most CRC patients. The current research was conducted to assess the effect of surgery or chemotherapy on gut microbiota. Forty-three CRC patients who received radical surgery and AC were enrolled. Fecal samples were collected preoperatively, postoperatively, and after the first to fifth cycles of postoperative chemotherapy. The microbial community of each sample was analyzed using high throughput 16S rRNA amplicon sequencing. Compared with preoperative samples, fecal samples collected postoperatively exhibited a significant decrease of obligate anaerobes, tumor-related bacteria, and butyric acid-producing bacteria. However, a significant increase of some conditional pathogens was observed. In addition, the AC regimen (CapeOx) was found to alter intestinal microbiota dramatically. In particular, several changes were observed after chemotherapy including an increase of pathogenic bacteria, the “rebound effect” of chemotherapy-adapted bacteria, the shift of lactate-utilizing microbiota from Veillonella to Butyricimonas and Butyricicoccus, as well as the decrease of probiotics. Both radical surgery and CapeOx chemotherapy exert a non-negligible effect on the gut microbiota of CRC patients. Microbiota-based intervention may be beneficial for patients during postoperative clinical management.
Keywordssurgery chemotherapy intestinal microbiota colorectal cancer
Unable to display preview. Download preview PDF.
This work was supported by the National Natural Science Foundation of China (81230057, 81372615, 81472262 and 81200264), the Emerging Cutting-Edge Technology Joint Research Projects of Shanghai (SHDC12012106) and Tongji University Subject Pilot Program (162385), Lijieshou Intestinal Barrier Foundation (LJS-201701), Specialized Research Fund for the Combine Traditional Chinese and Western Medicine in General Hospital of Shanghai (ZHYY-ZXYJHZX-1-201704).
Compliance and ethics The author(s) declare that they have no conflict of interest.
- Bloom, S.M., Bijanki, V.N., Nava, G.M., Sun, L., Malvin, N.P., Donermeyer, D.L., Dunne Jr., W.M., Allen, P.M., and Stappenbeck, T. S. (2011). Commensal Bacteroides species induce colitis in hostgenotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe 9, 390–403.CrossRefGoogle Scholar
- Danno, K., Hata, T., Tamai, K., Fujie, Y., Ide, Y., Kim, H.M., Ohnishi, T., Morita, S., Yoshioka, S., Kudo, T., et al. (2017). Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer. Cancer Chemother Pharmacol 80, 777–785.CrossRefGoogle Scholar
- Erlanger, D., Assous, M.V., Wiener-Well, Y., Yinnon, A.M., and Ben-Chetrit, E. (2017) Clinical manifestations, risk factors and prognosis of patients with Morganella morganii sepsis. J Microbiol Immunol Infection.Google Scholar
- Hill, D.A., Hoffmann, C., Abt, M.C., Du, Y., Kobuley, D., Kirn, T.J., Bushman, F.D., and Artis, D. (2010). Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in intestinal microbiota with associated alterations in immune cell homeostasis. Mucosal Immunol 3, 148–158.CrossRefGoogle Scholar
- Liu, Z., Qin, H., Yang, Z., Xia, Y., Liu, W., Yang, J., Jiang, Y., Zhang, H., Yang, Z., Wang, Y., et al. (2011). Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and postoperative infectious complications in colorectal cancer surgery - a double-blind study. Alimentary Pharmacol Therapeutics 33, 50–63.CrossRefGoogle Scholar
- Miquel, S., Leclerc, M., Martin, R., Chain, F., Lenoir, M., Raguideau, S., Hudault, S., Bridonneau, C., Northen, T., Bowen, B., et al. (2015). Identification of Metabolic Signatures Linked to Anti-Inflammatory Effects of Faecalibacterium prausnitzii. mBio 6.Google Scholar
- Montassier, E., Batard, E., Massart, S., Gastinne, T., Carton, T., Caillon, J., Le Fresne, S., Caroff, N., Hardouin, J.B., Moreau, P., et al. (2014). 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation. Microb Ecol 67, 690–699.CrossRefGoogle Scholar
- Nagasaka, T., Mishima, H., Sawaki, A., Shimokawa, M., Inukai, M., Shinozaki, K., Tanioka, H., Nasu, J., Nishina, T., Hazama, S., et al. (2016). Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/ mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study. BMJ Open 6, e011454.CrossRefGoogle Scholar
- Ponziani, F.R., Bhoori, S., Castelli, C., Putignani, L., Rivoltini, L., Del Chierico, F., Sanguinetti, M., Morelli, D., Paroni Sterbini, F., Petito, V., et al. (2019). Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology 69, 107–120.CrossRefGoogle Scholar
- Stringer, A.M., Gibson, R.J., Logan, R.M., Bowen, J.M., Yeoh, A.S.J., Hamilton, J., and Keefe, D.M.K. (2009). Gastrointestinal microflora and mucins may play a critical role in the development of 5- fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) 234, 430–441.CrossRefGoogle Scholar
- Touchefeu, Y., Montassier, E., Nieman, K., Gastinne, T., Potel, G., Bruley des Varannes, S., Le Vacon, F., and de La Cochetière, M.F. (2014). Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis—current evidence and potential clinical applications. Aliment Pharmacol Ther 22.Google Scholar
- van Vliet, M.J., Tissing, W.J.E., Dun, C.A.J., Meessen, N.E.L., Kamps, W. A., de Bont, E.S.J.M., and Harmsen, H.J.M. (2009). Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut. Clin Infect Dis 49, 262–270.CrossRefGoogle Scholar
- Vanlancker, E., Vanhoecke, B., Stringer, A., and Van de Wiele, T. (2017). 5- Fluorouracil and irinotecan (SN-38) have limited impact on colon microbial functionality and composition in vitro. Peer J 5, e4017.Google Scholar